Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

11.05.2026

1 Am J Respir Cell Mol Biol
8 Am J Respir Crit Care Med
1 BMC Cancer
2 Cancer Res
8 Clin Lung Cancer
2 Clin Nucl Med
2 Eur J Cancer
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
1 J Nucl Med
2 J Surg Oncol
5 J Thorac Cardiovasc Surg
1 J Thorac Oncol
1 JAMA Oncol
4 Lung Cancer
1 Mol Cancer Ther
1 Oncologist
1 Proc Natl Acad Sci U S A


    Am J Respir Cell Mol Biol

  1. DING H, Zhu X, Pan Y, Zhang Q, et al
    IGF2BP3-mediated NTSR1 m6A methylation enhances irinotecan resistance and lung adenocarcinoma malignant progression.
    Am J Respir Cell Mol Biol. 2026;74:364-374.
    >> Share


    Am J Respir Crit Care Med

  2. NANA-SINKAM P
    Toward Precision in Lung Cancer: Screening, Susceptibility, and Therapeutic Resistance.
    Am J Respir Crit Care Med. 2026 May 4:aamag228. doi: 10.1093.
    >> Share

  3. MANSOURI S, Pullamsetti SS, Savai R
    Spatial niches shape early oncogene-driven lung cancer: Anatomy as destiny.
    Am J Respir Crit Care Med. 2026 Apr 15:aamag195. doi: 10.1093.
    >> Share

  4. WILLIAMS RM
    Beyond Age and Pack-Years: Consideration of Alternative Criteria to Identify Asian-Americans for Lung Cancer Screening.
    Am J Respir Crit Care Med. 2026 Apr 10:aamag192. doi: 10.1093.
    >> Share

  5. FUCITO LM, Rojewski AM, Tanoue L, Bernstein SL, et al
    NRT Starter Packs and Gain-Framed Messages to Promote Smoking Cessation in Lung Cancer Screening: A Randomized Trial.
    Am J Respir Crit Care Med. 2026 Apr 24:aamag188. doi: 10.1093.
    >> Share

  6. WAQAS A, Rasool G, Schabath MB
    Trans-omics Gene-Smoking Interactions: A New Framework for Stratifying Smoking-Related Lung Cancer Risk.
    Am J Respir Crit Care Med. 2026 Feb 25:aamag094. doi: 10.1093.
    >> Share

  7. MENG F, Xia Z, Wang S, Wang Q, et al
    Hypoxic niche drives lineage imbalance and early tumorigenesis in EGFR-mutant lung cancer.
    Am J Respir Crit Care Med. 2026 Mar 25:aamag150. doi: 10.1093.
    >> Share

  8. CHOI E, Shusted C, Yang H, Evans H, et al
    Impact of Race and Acculturation on Lung Cancer Screening Eligibility: A Multi-Center Lung Cancer Cohort Study.
    Am J Respir Crit Care Med. 2026 Mar 19:aamag134. doi: 10.1093.
    >> Share

  9. CHENG DO, Yamada D, Azimbagirad M, Bhamani A, et al
    Expanded detection of early fibrotic phenotypes using lobar traction bronchiolectasis in lung cancer screening.
    Am J Respir Crit Care Med. 2026 Mar 10:aamag104. doi: 10.1093.
    >> Share


    BMC Cancer

  10. YANG G, Tian L, He D, Hu J, et al
    Aumolertinib in non-small cell lung cancer with uncommon EGFR exon 19 deletions: a real-world dual-center study.
    BMC Cancer. 2026 May 4. doi: 10.1186/s12885-026-16119.
    >> Share


    Cancer Res

  11. PATEL HV, Smith AE, Chan S, Gasendo JG, et al
    The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition.
    Cancer Res. 2026;86:2273-2285.
    >> Share

  12. WANG Y, Sheng X, Yang Y, Liu C, et al
    VGF-Mediated Mitochondrial Remodeling Fuels Lung Adenocarcinoma Brain Metastasis.
    Cancer Res. 2026;86:2104-2125.
    >> Share


    Clin Lung Cancer

  13. KASHIZAKI F, Orii R, Watanabe S, Yumoto K, et al
    Clinical Efficacy of HER2-targeted Monotherapy in ERBB2-mutant Non-Small-Cell Lung Cancer: A Systematic Review and Single-arm Meta-Analysis.
    Clin Lung Cancer. 2026 Apr 4:S1525-7304(26)00051.
    >> Share

  14. CATUREGLI G, Canavan M, Ayoade OF, Boffa DJ, et al
    Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer.
    Clin Lung Cancer. 2026 Apr 14:S1525-7304(26)00050.
    >> Share

  15. OGAWA-KOBAYASHI Y, Matsumoto I, Kuramoto J, Hoshi F, et al
    Erlotinib-Induced Ocular Cicatricial Pemphigoid in EGFR-Mutated Non-Small Cell Lung Cancer: A Case Report.
    Clin Lung Cancer. 2026;27:1-4.
    >> Share

  16. LEE M, Wang S, Sun L, Halmos B, et al
    To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC?
    Clin Lung Cancer. 2026;27:29-40.
    >> Share

  17. MURAKAMI K, Shimada Y, Hamaji M, Yamanashi K, et al
    Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.
    Clin Lung Cancer. 2026;27:141-148.
    >> Share

  18. KLEIN M, Watson D, Castro M, Kapoor S, et al
    Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2026;27:5-13.
    >> Share

  19. LE X, Serra E, Easson K, Bellefleur R, et al
    Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States.
    Clin Lung Cancer. 2026;27:41-46.
    >> Share

  20. WANG Z, Xu Y, Chen C, Ye M, et al
    Prognostic Analysis of Different Histological Types of 2-3 cm pN0M0 Carcinoma Based on Surgical Procedure: A SEER Database Study.
    Clin Lung Cancer. 2026;27:47-53.
    >> Share


    Clin Nucl Med

  21. ZHENG K, Li Q, Liu Y, Wang Y, et al
    A Primitive Endobronchial Tumor Derived by Salivary Gland on FDG PET/CT.
    Clin Nucl Med. 2026 Apr 2. doi: 10.1097/RLU.0000000000006457.
    >> Share

  22. LIN X, Xu T, Wang R, Huang D, et al
    177 Lu-FAP-2286 Therapy for Advanced Lung Adenocarcinoma With Multiple Metastases : A Promising Last-line Treatment Option.
    Clin Nucl Med. 2026;51:518-519.
    >> Share


    Eur J Cancer

  23. BLOCKER S, Kim D, Cavalieri CC, Cannon S, et al
    Corrigendum to "Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice" [Eur. J. Cancer 238 (May) (2026) 116686].
    Eur J Cancer. 2026;240:116772.
    >> Share

  24. VO-QUANG E, Campani C, Allaire M, Bouattour M, et al
    Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
    Eur J Cancer. 2026;239:116704.
    >> Share


    Int J Cancer

  25. FAN X, Wei C, Rong M, Wang S, et al
    Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.
    Int J Cancer. 2026;159:269-279.
    >> Share

  26. DIVER WR, Teras LR, Deubler EL, Patel AV, et al
    Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.
    Int J Cancer. 2026 May 3. doi: 10.1002/ijc.70530.
    >> Share


    Int J Radiat Oncol Biol Phys

  27. BOGART JA, Wang X, Masters G, Komaki R, et al
    Brief Report: Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: CALGB 30610 (Alliance) / RTOG 0538.
    Int J Radiat Oncol Biol Phys. 2026 May 3:S0360-3016(26)00688.
    >> Share


    J Clin Oncol

  28. WILLMANN J, Dee EC, Hendriks LEL, Dimitriou NM, et al
    Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.
    J Clin Oncol. 2026 May 5:JCO2501958. doi: 10.1200/JCO-25-01958.
    >> Share


    J Nucl Med

  29. NOVRUZOV E, Mamlins E, Widjaja L, Siegmund SC, et al
    Reliability and Practicability of FAP-RADS Version 1.0 for Structured Reporting of FAPI Imaging in Pulmonary and Urothelial Carcinoma.
    J Nucl Med. 2026;67:687-692.
    >> Share


    J Surg Oncol


  30. Correction to "Comparison of a Risk Calculator With Frailty Indices in Patients Undergoing Lung Cancer Resection".
    J Surg Oncol. 2026 May 2. doi: 10.1002/jso.70137.
    >> Share


  31. Correction to "Comparison of a Risk Calculator With Frailty Indices in Patients Undergoing Lung Cancer Resection".
    J Surg Oncol. 2026 May 2. doi: 10.1002/jso.70140.
    >> Share


    J Thorac Cardiovasc Surg

  32. CHEN T, Huang Y, Xue Y
    Risk stratification or treatment selection? Pathologic response and ypN status after neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2026 May 2:S0022-5223(26)00842.
    >> Share

  33. FERNANDEZ FG
    Commentary: When is enough, enough? Sublobar resection for high-risk lung cancer.
    J Thorac Cardiovasc Surg. 2026 Apr 30:S0022-5223(26)00959.
    >> Share

  34. FANG Y, Fan M, Chen H, Yu R, et al
    Surgical management of the primary tumor in stage M1a-IVA Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2026 May 2:S0022-5223(26)00907.
    >> Share

  35. LINDEN P, Martin LW, Stiles B, Opitz I, et al
    The 2026 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Evaluation and Management of N2+ Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2026 May 2:S0022-5223(26)00899.
    >> Share

  36. PAN H, Chen H, Xu Y, Ge Z, et al
    Optimizing Wedge Resection For Peripheral Clinical Stage IA1-2 Non-Small Cell Lung Cancer With Tumor Spread Through Air Spaces.
    J Thorac Cardiovasc Surg. 2026 May 5:S0022-5223(26)00965.
    >> Share


    J Thorac Oncol

  37. DEL RIO B, Masini S, Caceres-Galvis C, Torres-Jimenez J, et al
    Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2026 May 2:103899. doi: 10.1016/j.jtho.2026.103899.
    >> Share


    JAMA Oncol

  38. FOX AH, Ward RC, Alexander M, Osarogiagbon RU, et al
    Rates of Systemic Treatment for Metastatic Non-Small Cell Lung Cancer Among Older Adults.
    JAMA Oncol. 2026 May 7. doi: 10.1001/jamaoncol.2026.1080.
    >> Share


    Lung Cancer

  39. ITO M, Ariyasu R, Fujishima S, Iso H, et al
    Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy.
    Lung Cancer. 2026;217:109428.
    >> Share

  40. LIANG J, Feng Y, Gui D, Zheng X, et al
    A dynamic proteomic signature for the prediction of lung Cancer: a longitudinal analysis in the UK Biobank cohort.
    Lung Cancer. 2026;217:109424.
    >> Share

  41. IWAI C, Kimura Y, Matsui H, Fushimi K, et al
    Protective effect of bevacizumab against interstitial lung disease in non-squamous non-small-cell lung cancer: a nationwide target trial emulation study.
    Lung Cancer. 2026;217:109429.
    >> Share

  42. KANEDA H, Tachihara M, Toi Y, Kuyama S, et al
    Phase II study of ramucirumab plus erlotinib for treatment-naive patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).
    Lung Cancer. 2026;217:109432.
    >> Share


    Mol Cancer Ther

  43. GHAFOOR A, Zhu L, Weaver Ohler Z, El Meskini R, et al
    HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancer.
    Mol Cancer Ther. 2026 May 1. doi: 10.1158/1535-7163.MCT-25-1077.
    >> Share


    Oncologist

  44. DRILON A, Cho BC, Camidge DR, Nagasaka M, et al
    Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
    Oncologist. 2026;31:oyag137.
    >> Share


    Proc Natl Acad Sci U S A

  45. HE J, Lok CN, Yang G, He Y, et al
    A ginsenoside metabolite and its derivative target PRELID3B against lung cancer cells.
    Proc Natl Acad Sci U S A. 2026;123:e2533505123.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016